Medical Action Recalls Epidural Kits Over Sterility Risk

A supplier-induced sterility failure has escalated into a Class I correction at the kit level: Medical Action Industries has directed customers to quarantine and relabel epidural kits containing sodium chloride ampules traced back to a Huons Co., Ltd. manufacturing recall, with the FDA classifying the event as its most serious device correction category.

The correction covers sixteen lot numbers across two kit configurations, Epidural/Pain TQC 20/Cs (item 82465) and Single Shot Epidural 20/Cs (items 59553, 83945B), each identified by UDI. Affected kits may contain 0.9% sodium chloride, 10 mL flush ampules manufactured by Huons and distributed through Spectra Medical Devices, LLC. If sterility is compromised, patients face exposure to viable microorganisms, endotoxins, and foreign particulate matter. Given the epidural route of administration, the clinical consequences extend to meningeal infection, abscess formation, spinal root compression, and death.

For QA directors and incoming material control teams, the cascade structure here is instructive. The root failure originated at a component manufacturer (Huons), passed through a distributor (Spectra Medical Devices), and surfaced only at the finished-kit level (Medical Action Industries), a three-tier propagation that underscores the limits of supplier qualification programs that do not extend to sub-tier manufacturers. Under 21 CFR Part 820 and analogous pharma frameworks including ICH Q10, supplier control obligations do not terminate at the first-tier vendor.

Medical Action Industries issued customer letters on July 23, instructing facilities to identify, segregate, and quarantine impacted kits; affix warning labels in a prominently visible location without obscuring existing labeling; and remove and discard the sodium chloride flush ampules prior to any continued use of remaining kit components. UDI-based lot identification is the primary traceability mechanism cited for isolating affected inventory. No serious injuries or deaths had been reported as of the letter date.

Plant heads and supply-chain leads managing sterile component sourcing should treat this correction as a prompt to audit sub-tier supplier visibility within their own incoming material controls, particularly for finished kits or combination packs where a single compromised component can trigger a kit-wide Class I action.

The measurable checkpoint now sits with affected customers: full quarantine compliance and label application across all identified lot numbers before any remaining kit components re-enter clinical use.

Source: FDA MedWatch Safety Alerts via FDA.gov, September 10, 2026.